Chief Medical Officer Ed Ikeguchi to Present on UK’s Nationwide EDC Deployment; Senior Director Anne Zielinski to Highlight Data Integration Techniques
NEW YORK, NY – March 1, 2006 – Medidata Solutions, a global provider of electronic clinical data capture, management and reporting solutions, today announced that Chief Medical Officer Dr. Ed Ikeguchi and newly-appointed Senior Director of Strategic Alliances Anne Zielinski will each be presenting at the 18th Annual DIA EuroMeeting to be held March 6–8, 2006 at Le Palais des Congres in Paris, France.
Ikeguchi's presentation, to be delivered on Wednesday, March 8th at 12:30 p.m., is entitled "The Deployment of Technology Platforms and Electronic Data Capture (EDC) on a National Level: Experience with the National Health Service (NHS) in the United Kingdom." In this seminar, Ikeguchi will present a case study of the UK's government-sponsored effort to improve clinical trials quality and stimulate enrollment through the NHS and the National Cancer Research Network (NCRN). Ikeguchi plans to discuss how standardizing technology as a single platform across an entire nation requires unique considerations for successful implementation.
Zielinski's presentation, "Importing and Exporting Data from EDC – Options and Experiences" on Wednesday, March 8th at 11:00 a.m., will illustrate how increased use of EDC has brought demands for integration of data from various sources. Attendees will learn how data has been integrated, what workflows have been used for integrated data, and how to avoid issues when integrating data.
At this year's show, Medidata Solutions will also be demonstrating its Rave electronic clinical data management solution at booth #55. In addition to showcasing technologies like Rave, the conference will offer attendees an opportunity to learn about the challenges of the revised pharmaceutical legislation and witness the release of the latest developments in important initiatives in Europe.
As one of Medidata's founders and the company's Chief Medical Officer, Ikeguchi focuses on regulatory compliance and 21 CFR Part 11 and is responsible for ensuring defined project goals, objectives, development strategy, resource requirements and scheduling. Prior to forming Medidata Solutions in 2000, Ikeguchi served as assistant professor of clinical urology at Columbia University and held hospital appointments at Columbia Presbyterian, Helen Hayes Hospital and White Plains Hospitals Center. Ikeguchi has served as a clinical investigator in numerous trials sponsored by both the industry and NIH, with experience in technology-based processes related to the pharmaceutical and biotechnology industries. Ikeguchi is a regularly featured presenter at DIA and other industry events.
Zielinski joined Medidata as senior director of strategic alliances in December of 2005. Zielinski had previously served as vice President of strategic alliances at CB Technologies and vice president of business development at WebMD. Zielinski brings 10 years of experience in the EDC industry and is a frequent presenter at key industry events including SCDM and DIA meetings.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.